Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin in Impaired and Normal Glucose Tolerance
NCT05468229Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Sponsor
- The Chinese University of Hong Kong
- Modality
- Small Molecules
- Drugs
- dorzagliatin
- Conditions
- glucose intolerance
01
Overview
Phase 2, randomised trial in glucose intolerance comparing Dorzagliatin Sequence with Placebo Sequence (2 arms). Primary endpoint: 2-hour hyperglycemic clamp. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Dorzagliatin Sequence
Participants receive Dorzagliatin in Period 1 and Placebo in Period 2
Placebo Sequence
Participants receive Placebo in Period 1 and Dorzagliatin in Period 2
03
Who it enrols
Individuals aged 18-65 with BMI 18-30 kg/m2, including both those with impaired glucose tolerance (IGT) and normal glucose tolerance (NGT), who have never been treated with glucose-lowering drugs.
04
Endpoints
Primary
2-hour hyperglycemic clamp
Beyond the preview
Go deeper on NCT05468229.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468229.